Join the Amyloidogenic Transthyretin Amyloidosis group to help and get support from people like you.
Amyloidogenic Transthyretin Amyloidosis News
Related terms: Transthyretin-Related Amyloidosis, hATTR, Hereditary Transthyretin-Related Amyloidosis
Acoramidis Beneficial in Transthyretin Amyloid Cardiomyopathy
THURSDAY, Jan. 11, 2024 – Acoramidis yields a significantly better four-step primary hierarchical outcome, including aspects of mortality and morbidity, than placebo for patients with transthyretin...
FDA Approves Wainua (eplontersen) for the Treatment of Adults with Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
U.S. FDA approval based on Phase 3 NEURO-TTRansform results showing Wainua demonstrated consistent and sustained benefit halting neuropathy disease progression and improving neuropathy impairment...
Patisiran Can Preserve Functional Capacity in ATTR Amyloidosis
THURSDAY, Oct. 26, 2023 – For patients with transthyretin amyloidosis (ATTR amyloidosis), administration of an RNA interference therapeutic agent, patisiran, over 12 months results in preserved...
Prognostic Factors ID'd for Stage IIIb AL Amyloidosis
THURSDAY, Aug. 24, 2023 – For patients with stage IIIb amyloid light chain (AL) amyloidosis, baseline factors predictive of treatment outcomes and survival have been identified, according to a study...
FDA Approves Amvuttra (vutrisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 13, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration...
FDA Approves Tegsedi (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
BOSTON and CARLSBAD, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) – Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
FDA Approves Onpattro (patisiran) Targeted RNA-based Therapy for Polyneuropathy Caused by hATTR
August 10, 2018 – The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary...
Ask a question
To post your own question to this support group, sign in or create an account.